[Tacrolimus for therapy of rheumatoid arthritis].
Harigai
Masayoshi
M
Clinical Research Center, Department of Medicine and Rheumatology, Tokyo Medical and Dental University.
D000818:Animals; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004268:DNA-Binding Proteins / Q000378:metabolism; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D007564:Japan; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014157:Transcription Factors / Q000378:metabolism; D014481:United States
D018501:Antirheumatic Agents; D004268:DNA-Binding Proteins; D007376:Interleukin-2; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D014157:Transcription Factors; D016559:Tacrolimus